scholarly journals Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo

2010 ◽  
Vol 36 (5) ◽  
Author(s):  
Albers
Oncotarget ◽  
2016 ◽  
Vol 8 (10) ◽  
pp. 16190-16201 ◽  
Author(s):  
Leisa Lopes-Aguiar ◽  
Ericka Francislaine Dias Costa ◽  
Guilherme Augusto Silva Nogueira ◽  
Tathiane Regine Penna Lima ◽  
Marília Berlofa Visacri ◽  
...  

Cancer ◽  
2002 ◽  
Vol 94 (2) ◽  
pp. 393-397 ◽  
Author(s):  
Lie Cheng ◽  
Erich M. Sturgis ◽  
Susan A. Eicher ◽  
Margaret R. Spitz ◽  
Qingyi Wei

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 6061-6061 ◽  
Author(s):  
H. Jun ◽  
M. Ahn ◽  
H. Kim ◽  
B. Park ◽  
J. Han ◽  
...  

6061 Background: The cytotoxic effect of cisplatin is based on the DNA cross linking. Nucleotide excision repair is associated with resistant to platinum-based chemotherapy. The excision repair cross-complementation group 1 (ERCC1) enzyme plays a rate-limiting role in nucleotide excision repair pathway. We evaluated the expression of ERCC1 as a predictive factor for survival in patients of squamous cell carcinoma of the head and neck (SCCHN) treated with cisplatin-based concurrent chemoradiotherapy (CCRT). Methods: We reviewed the clinical records and pathologic specimens of locally advanced SCCHN patients who had been treated with cisplatin-based definitive CCRT between 1995 and 2005. ERCC1 expression of the biopsy specimen was assessed by immunohistochemical (IHC) staining and a semi- quantitative grading system (H-score) was used for the evaluation. The median value of the H-score was chosen as the cutoff point for positive ERCC1 expression. Results: A total of 44 specimens and clinical data of the patients were reviewed. The median age was 59 years (range; 27–75), and 81.8% were male; 94.2% had ECOG performance status 0–1. The positive ERCC1 expression rate was 54.5% of all specimens (N=24/44). Overall tumor response rate for CCRT was 90.9% (CR=65.9%; PR=25.0%). With a median follow-up of 45.9 months (range; 5.4–133.0), 5-year progression free survival (PFS) rate was 58.0% and 5-year overall survival (OS) rate was 57.2%. Patients in group of positive ERCC1 expression showed poor survival in terms of PFS and OS (p=0.04; p=0.05), compared with negative ERCC1 expression group. Conclusions: The positive ERCC1 expression might be a predictive factor for poor survival and early progression in patients with locally advanced SCCHN treated with cisplatin-based CCRT. No significant financial relationships to disclose.


2011 ◽  
Vol 18 (2) ◽  
pp. 191-197 ◽  
Author(s):  
Marcin Jaciuk ◽  
Elżbieta Nowak ◽  
Krzysztof Skowronek ◽  
Anna Tańska ◽  
Marcin Nowotny

2000 ◽  
Vol 460 (3-4) ◽  
pp. 277-300 ◽  
Author(s):  
Karsten Theis ◽  
Milan Skorvaga ◽  
Mischa Machius ◽  
Noriko Nakagawa ◽  
Bennett Van Houten ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document